UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest
event reported): December 2, 2008
|
DELCATH
SYSTEMS, INC.
|
|
(Exact
Name of Registrant as Specified in
Charter)
|
|
DELAWARE
|
001-16133
|
06-1245881
|
||
|
(State
of Incorporation)
|
(Commission
File
Number)
|
(IRS
Employer
Identification
No.)
|
|
600
FIFTH AVENUE, 23rd
FLOOR
NEW
YORK, NEW YORK
|
|
10020
|
|
(Address
of Principal Executive Offices)
|
(Zip
Code)
|
Registrant's
telephone number, including area code: (212) 489-2100
Check the
appropriate box below if the Form 8−K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
[ ]
Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
[ ]
Soliciting material pursuant to Rule 14a−12 under the Exchange Act (17 CFR
240.14a−12)
[ ]
Pre−commencement communications pursuant to Rule 14d−2(b) under the Exchange Act
(17 CFR 240.14d−2(b))
[ ]
Pre−commencement communications pursuant to Rule 13e−4(c) under the Exchange Act
(17 CFR 240.13e−4(c))
Item
5.02. Departure of Directors or Certain Officers;
Election of Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.
Jonathan Lewis,
M.D., Ph.D., has stepped down from his position as a director of the Company,
effective December 2, 2008. Dr. Lewis advised the Company that his decision to
leave the Delcath board is a result of additional commitments to new leadership
positions.
Dr.
Harold Koplewicz, Chairman of the Board of Directors of Delcath, commented, "We
all thank Jon for his dedicated service to Delcath and wish him the best in his
future professional pursuits."
Item
9.01 Financial Statements and Exhibits
(d) Exhibits
|
Exhibit
Number
|
Description |
|
99.1
|
Press
Release
|
SIGNATURES
Pursuant to the requirements of the
Securities Exchange Act of 1934, the Registrant has duly caused this report to
be signed on its behalf by the undersigned hereunto duly
authorized.
Date: December
4, 2008
| DELCATH SYSTEMS, INC. | |||
|
|
By:
|
/s/ Paul M. Feinstein | |
| Name: Paul M. Feinstein | |||
| Title: Chief Financial Officer | |||
Exhibit
99.1
JONATHAN
LEWIS, M.D., Ph.D. STEPS DOWN FROM DELCATH SYSTEMS BOARD OF
DIRECTORS
New York,
NY (December 4, 2008) - Delcath Systems, Inc. (Nasdaq: DCTH) today announced
that Jonathan Lewis, M.D., Ph.D., has stepped down from his position as a
director of the Company, effective December 2, 2008. Dr. Lewis advised the
Company that his decision to leave the Delcath board is a result of additional
commitments to new leadership positions.
Dr.
Harold Koplewicz, Chairman of the Board of Directors of Delcath Systems,
commented, "We all thank Jon for his dedicated service to Delcath and wish him
the best in his future professional pursuits."
About
Delcath Systems, Inc.
Delcath
Systems, Inc. is a medical technology company specializing in cancer
treatment. The Company has developed a proprietary, patented system
designed to improve the efficacy of cancer treatment while reducing the
considerable, systemic side-effects of chemotherapy. Delcath's novel
drug delivery platform is capable of delivering anti-cancer drugs at very high
doses to a specific organ or region of the body while preventing these high
doses of drug from entering the patient's bloodstream. The Company is
currently enrolling patients in Phase III and Phase II clinical studies for the
treatment of liver cancers using high doses of melphalan. The
Company's intellectual property portfolio consists of twenty-eight patents on a
worldwide basis including the U.S., Europe, Asia and Canada. For more
information, please visit the Company's website at www.delcath.com.
This
release contains express or implied forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 that are based
on the current belief of management. These statements relate to,
among other things, the results to date of our phase III clinical trials as
described above. These statements are neither promises nor
guarantees, but are subject to a variety of risks and uncertainties, many of
which are beyond our control, and which could cause actual results to differ
materially from those contemplated in these forward-looking
statements. In particular, the risks and uncertainties include, among
other things: risks that any results of any trials to date are interim and may
not be borne out or supported by subsequent or final results or that any such
trials may not be fully completed as necessary; risks relating to our ability to
further advance the development of the our system in clinical trials; risks of
any failure to comply with regulations relating to our system, including FDA
requirements; risks of failure to obtain the financial resources to complete
development of our system; the risk that the FDA may interpret the results of
our studies differently from any interpretation we may have; and all of the
other risks discussed from time to time in our filings with the Securities and
Exchange Commission, including our most recent Annual Report on Form 10-K and
subsequent Quarterly Reports on Form 10-Q. You should not place undue
reliance on these forward-looking statements, which speak only as of the date
they are made. We undertake no obligation to publicly update or
revise these forward-looking statements to reflect events or circumstances after
the date they are made.
Contact:
Company
Contact:
Delcath
Systems, Inc.
Richard
L. Taney
(212)
489-2100
rtaney@delcath.com
Investor
Relations Contact:
Strategic
Growth International, Inc.
Richard
E. Cooper
(212)
838-1444
rcooper@sgi-ir.com
Public
Relations Contact:
Rubenstein
Associates, Inc.
Robin
Wagge
(212)
843-8006
rwagge@Rubenstein.com